The International Agency for Research on Cancer (IARC) released its 2025-2029 Priority List for evaluation in April of this ...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with ...

The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate ß-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in ...

Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either ...